(firstQuint)To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis.

 Phase 2a, randomized, placebo-controlled, pilot study in up to 21 adult patients with moderate to severe CCh.

 Eligible patients will be randomly assigned in a 2:1 (active:placebo) ratio to one of two treatment groups, LO2A or placebo.

 This study with 4 visits, will consist of a screening period of up to 2 weeks and a 3-month treatment period (topical, OU, QID application of eye drops).

.

 To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis@highlight

A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients with Moderate to Severe Conjunctivochalasis